Indivior Pharmaceuticals (INDV) Common Equity (2022 - 2025)
Historic Common Equity for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to -$207.0 million.
- Indivior Pharmaceuticals' Common Equity fell 2395.21% to -$207.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$207.0 million, marking a year-over-year decrease of 2395.21%. This contributed to the annual value of -$337.0 million for FY2024, which is 8315.22% down from last year.
- Indivior Pharmaceuticals' Common Equity amounted to -$207.0 million in Q3 2025, which was down 2395.21% from -$257.0 million recorded in Q2 2025.
- Indivior Pharmaceuticals' 5-year Common Equity high stood at $117.0 million for Q2 2023, and its period low was -$337.0 million during Q4 2024.
- For the 4-year period, Indivior Pharmaceuticals' Common Equity averaged around -$127.6 million, with its median value being -$167.0 million (2024).
- Data for Indivior Pharmaceuticals' Common Equity shows a peak YoY increase of 2395.21% (in 2025) and a maximum YoY decrease of 295000.0% (in 2025) over the last 5 years.
- Over the past 4 years, Indivior Pharmaceuticals' Common Equity (Quarter) stood at $51.0 million in 2022, then crashed by 460.78% to -$184.0 million in 2023, then crashed by 83.15% to -$337.0 million in 2024, then skyrocketed by 38.58% to -$207.0 million in 2025.
- Its Common Equity was -$207.0 million in Q3 2025, compared to -$257.0 million in Q2 2025 and -$285.0 million in Q1 2025.